Effect_NN of_IN hemofiltration_NN filter_NN adsorption_NN on_IN circulating_VBG IL-6_JJ levels_NNS in_IN septic_JJ rats_NNS Abstract_NP |_SYM Introduction_NP |_SYM Hemofiltration_NN may_MD modulate_VB the_DT inflammatory_JJ response_NN in_IN sepsis_NN through_IN a_DT variety_NN of_IN mechanisms_NNS ._SENT We_PP sought_VBD to_TO distinguish_VB clearance_NN from_IN adsorption_NN as_IN the_DT principal_JJ mechanism_NN responsible_JJ for_IN reducing_VBG circulating_VBG IL-6_JJ levels_NNS with_IN hemofiltration_NN ._SENT Materials_NNS and_CC methods_NNS |_SYM Nine_CD hours_NNS after_IN cecal_JJ ligation_NN and_CC puncture_NN in_IN 18_CD adult_NN male_JJ Sprague_NP --_: Dawley_NP rats_NNS ,_, we_PP divided_VBD the_DT rats_NNS into_IN three_CD groups_NNS (_( 6_CD animals_NNS each_DT )_) and_CC placed_VBD groups_NNS 2_CD and_CC 3_CD on_IN a_DT hemofiltration_NN circuit_NN connected_VBN between_IN the_DT right_JJ carotid_JJ artery_NN and_CC femoral_JJ vein_NN using_VBG an_DT AN69_NP membrane_NN ._SENT In_IN the_DT hemofiltration_NN group_NN (_( group_NN 2_CD )_) ,_, ultrafiltrate_NN was_VBD replaced_VBN with_IN lactated_VBN Ringer_NP 's_POS solution_NN ;_: in_IN the_DT recirculation_NN group_NN (_( group_NN 3_CD )_) ,_, the_DT ultrafiltrate_NN was_VBD reinfused_VBN into_IN the_DT animal_NN ._SENT A_DT sham_JJ group_NN (_( group_NN 1_CD )_) had_VBD an_DT arteriovenous_JJ circuit_NN inserted_VBN but_CC no_DT hemofiltration_NN ._SENT Blood_NN was_VBD obtained_VBN for_IN measurement_NN of_IN IL-6_NP and_CC tumor_NN necrosis_NN factor_NN (_( TNF_NP )_) at_IN the_DT start_NN of_IN hemofiltration_NN and_CC after_IN 5_CD and_CC 11_CD hours_NNS of_IN treatment_NN ._SENT Results_NNS and_CC discussion_NN |_SYM IL-6_JJ levels_NNS increased_VBD only_RB in_IN the_DT sham-treated_JJ animals_NNS (_( 20.4_CD +-_NN 11.3_CD at_IN baseline_NN to_TO 62.3_CD +-_NN 16.8_CD pg/ml_NN at_IN 11_CD hours_NNS ,_, P_NN =_SYM 0.03_CD )_) (_( differences_NNS between_IN groups_NNS 1_CD and_CC 2_CD ,_, P_NN =_SYM 0.015_CD ,_, and_CC groups_VBZ 1_CD and_CC 3_CD ,_, P_NN =_SYM 0.028_CD )_) ._SENT TNF_NP levels_NNS were_VBD highly_RB variable_JJ but_CC not_RB significantly_RB different_JJ among_IN the_DT three_CD groups_NNS ._SENT Conclusion_NN |_SYM Hemofiltration-associated_JJ reductions_NNS in_IN circulating_VBG IL-6_NP levels_NNS appear_VBP to_TO be_VB secondary_JJ to_TO adsorption_NN of_IN mediators_NNS to_TO the_DT filter_NN membrane_NN ._SENT We_PP do_VBP not_RB know_VB whether_IN this_DT is_VBZ due_JJ to_TO direct_VB adsorption_NN of_IN IL-6_NP per_FW se_FW or_CC to_TO the_DT absorption_NN of_IN other_JJ mediators_NNS with_IN secondary_JJ downregulation_NN of_IN IL-6_NP production_NN or_CC release_NN ._SENT In_IN addition_NN ,_, we_PP could_MD not_RB exclude_VB an_DT interaction_NN between_IN adsorption_NN and_CC hemofiltration_NN ._SENT continuous_JJ renal_JJ replacement_NN therapy_NN ,_, cytokines_NNS ,_, hemofiltration_NN ,_, interleukins_NNS ,_, sepsis_NN ,_, tumor_NN necrosis_NN factor_NN ,_, Numerous_JJ studies_NNS have_VBP shown_VBN that_IN hemofiltration_NN using_VBG porous_JJ synthetic_JJ membranes_NNS can_MD and_CC does_VBZ remove_VB a_DT wide_JJ range_NN of_IN substances_NNS that_WDT mediate_VBP inflammation_NN from_IN the_DT plasma_NN ._SENT Limited_JJ evidence_NN supports_VBZ the_DT notion_NN that_IN this_DT treatment_NN can_MD also_RB influence_VB circulating_VBG plasma_NN concentrations_NNS of_IN various_JJ mediators_NNS and_CC mounting_VBG evidence_NN suggests_VBZ that_IN these_DT manipulations_NNS have_VBP important_JJ biologic_JJ effects_NNS ._SENT Despite_IN these_DT advances_NNS ,_, there_EX are_VBP no_RB randomized_VBN clinical_JJ trials_NNS demonstrating_VBG that_DT hemofiltration_NN improves_VBZ outcome_NN in_IN patients_NNS with_IN sepsis_NN ._SENT Furthermore_RB ,_, the_DT exact_JJ mechanisms_NNS responsible_JJ for_IN immunomodulation_NN with_IN hemofiltration_NN remain_VBP uncertain_JJ ._SENT Modern_JJ hemofiltration_NN filters_NNS may_MD adsorb_VB mediator_NN substances_NNS as_RB well_RB as_IN permitting_VBG them_PP to_TO pass_VB through_IN the_DT membrane_NN ._SENT Determining_VBG which_WDT of_IN these_DT mechanisms_NNS is_VBZ dominant_JJ will_MD be_VB essential_JJ to_TO advancing_VBG the_DT design_NN of_IN materials_NNS and_CC methodology_NN suited_VBN to_TO this_DT form_NN of_IN therapy_NN ._SENT If_IN adsorption_NN is_VBZ the_DT primary_JJ effect_NN ,_, the_DT surface_NN area_NN of_IN the_DT filters_NNS must_MD be_VB increased_VBN ,_, perhaps_RB by_IN using_VBG beads_NNS rather_RB than_IN filaments_NNS ._SENT Conversely_RB ,_, if_IN mediator_NN substances_NNS are_VBP removed_VBN mainly_RB by_IN sieving_VBG ,_, increases_NNS in_IN ultrafiltration_NN rates_NNS will_MD be_VB required_VBN ._SENT We_PP undertook_VBD these_DT experiments_NNS to_TO determine_VB whether_IN adsorption_NN alone_RB could_MD affect_VB the_DT inflammatory_JJ state_NN of_IN rats_NNS with_IN sepsis_NN in_IN a_DT manner_NN similar_JJ to_TO standard_JJ hemofiltration_NN ._SENT We_PP chose_VBD to_TO measure_VB interleukin-6_JJ (_( IL-6_NP )_) as_IN a_DT marker_NN of_IN the_DT activation_NN status_NN of_IN the_DT cytokine_JJ network_NN because_IN it_PP is_VBZ known_VBN to_TO persist_VB for_IN several_JJ hours_NNS in_IN the_DT circulation_NN and_CC reflects_VBZ the_DT influences_NNS of_IN several_JJ other_JJ cytokines_NNS ._SENT Although_IN IL-6_NP is_VBZ not_RB cytotoxic_JJ ,_, circulating_VBG IL-6_NP is_VBZ reproducibly_RB detectable_JJ in_IN patients_NNS with_IN sepsis_NN ,_, and_CC higher_JJR concentrations_NNS portend_VBP a_DT poor_JJ outcome_NN ._SENT For_IN these_DT reasons_NNS ,_, IL-6_NP has_VBZ increasingly_RB been_VBN used_VBN a_DT marker_NN of_IN the_DT inflammatory_JJ response_NN in_IN clinical_JJ trials_NNS of_IN investigational_JJ agents_NNS in_IN sepsis_NN ._SENT We_PP also_RB measured_VBD tumor_NN necrosis_NN factor_NN (_( TNF_NP )_) in_IN an_DT effort_NN to_TO correlate_VB changes_NNS in_IN IL-6_NP with_IN TNF_NP activity_NN during_IN the_DT same_JJ period_NN ._SENT Surgical_JJ preparation_NN |_SYM After_IN approval_NN by_IN the_DT Animal_NP Care_NP and_CC Use_NP Committee_NP of_IN the_DT University_NP of_IN Pittsburgh_NP Medical_NP Center_NP ,_, we_PP anesthetized_VBD 20_CD adult_NN ,_, male_JJ Sprague_NP --_: Dawley_NP rats_NNS (_( mean_JJ weight_NN 486_CD g_NN )_) with_IN pentobarbital_JJ sodium_NN (_( 50_CD mg/kg_NNS intraperitoneally_RB )_) ._SENT We_PP performed_VBD a_DT midline_NN laparotomy_NN ,_, exteriorized_VBD the_DT cecum_NN ,_, and_CC placed_VBD a_DT ligature_NN inferior_JJ to_TO the_DT ileocecal_JJ valve_NN using_VBG 4_CD --_: 0_CD silk_NN ._SENT We_PP punctured_VBD the_DT cecum_NN three_CD times_NNS using_VBG a_DT sterile_JJ 18-gauge_JJ needle_NN ,_, placing_VBG one_CD puncture_NN site_NN on_IN each_DT of_IN the_DT three_CD antimesenteric_JJ surfaces_NNS ._SENT We_PP then_RB returned_VBD the_DT cecum_NN to_TO the_DT abdominal_JJ cavity_NN and_CC closed_VBD with_IN 2_CD --_: 0_CD suture_NN ._SENT We_PP then_RB administered_VBD a_DT subcutaneous_JJ bolus_NN of_IN saline_JJ (_( 50_CD ml/kg_NN )_) as_IN fluid_JJ resuscitation_NN and_CC returned_VBD the_DT animals_NNS to_TO their_PP$ cages_NNS and_CC allowed_VBN food_NN and_CC water_NN ad_NN libitum_NN ._SENT In_IN two_CD animals_NNS ,_, we_PP obtained_VBD serial_JJ blood_NN samples_NNS each_DT hour_NN for_IN 24_CD hours_NNS and_CC measured_VBN IL-6_NP and_CC TNF_NP concentrations_NNS ._SENT The_DT results_NNS from_IN these_DT animals_NNS were_VBD used_VBN to_TO plan_VB the_DT experiments_NNS for_IN the_DT remaining_VBG groups_NNS ._SENT We_PP randomized_VBD the_DT remaining_VBG 18_CD rats_NNS into_IN three_CD groups_NNS ._SENT Seven_CD hours_NNS after_IN the_DT cecal_JJ ligation_NN and_CC puncture_VB (_( CLP_NP )_) ,_, we_PP reanesthetized_VBD each_DT animal_NN and_CC intubated_VBD it_PP with_IN a_DT beveled_JJ ,_, 16-gauge_JJ angiocatheter_NN and_CC ventilated_VBD it_PP with_IN room_NN air_NN using_VBG a_DT Harvard_NP rodent_NN ventilator_NN (_( Holliston_NP ,_, MA_NP ,_, USA_NP )_) at_IN a_DT tidal_JJ volume_NN of_IN 10_CD ml/kg_NN and_CC a_DT frequency_NN sufficient_JJ to_TO maintain_VB an_DT arterial_JJ PCO2_NN between_IN 35_CD and_CC 45_CD mmHg_NN ._SENT We_PP isolated_VBD the_DT right_JJ carotid_JJ artery_NN and_CC the_DT left_JJ femoral_JJ vein_NN by_IN dissection_NN and_CC cannulated_VBD each_DT with_IN 1.27-mm_NP PE-90_NP tubing_NN ._SENT The_DT tubing_NN was_VBD formed_VBN into_IN a_DT catheter_NN by_IN inserting_VBG a_DT beveled_JJ 20-gauge_JJ needle_NN into_IN one_CD end_NN ._SENT We_PP flushed_VBD each_DT cannula_NN with_IN heparinized_JJ saline_NN (_( 2000_CD units/liter_NN )_) ._SENT We_PP placed_VBD a_DT 3-way_JJ stopcock_NN on_IN each_DT catheter_NN so_IN that_DT blood_NN sampling_NN could_MD be_VB achieved_VBN using_VBG the_DT carotid_JJ arterial_JJ catheter_NN and_CC fluid_NN could_MD be_VB administered_VBN through_IN the_DT venous_JJ catheter_NN ._SENT Experimental_JJ procedure_NN |_SYM Nine_CD hours_NNS after_IN CLP_NP ,_, we_PP connected_VBD the_DT arterial_JJ and_CC venous_JJ catheters_NNS for_IN animals_NNS in_IN groups_NNS 2_CD and_CC 3_CD to_TO a_DT clamped_VBN hemofilter_NN with_IN an_DT AN-69_NP membrane_NN (_( Miniflow-10_NP ,_, Hospal_NP ,_, Lyon_NP ,_, France_NP )_) ,_, surface_NN area_NN =_SYM 0.042_CD m2_NN ,_, fiber_NN internal_JJ diameter_NN 240_CD mum_NN ,_, fiber_NN wall_NN thickness_NN 50_CD m._NNS The_DT filter_NN ,_, which_WDT had_VBD been_VBN flushed_VBN with_IN sterile_JJ saline_NN only_RB ,_, was_VBD flushed_VBN with_IN 5000_CD unit/liter_NN heparinized_JJ saline_NN immediately_RB before_IN the_DT circuit_NN was_VBD opened_VBN ._SENT For_IN animals_NNS in_IN group_NN 1_CD ,_, we_PP connected_VBD the_DT arterial_JJ and_CC venous_JJ cannulas_NNS to_TO each_DT other_JJ and_CC we_PP removed_VBD 3_CD ml_NN of_IN blood_NN to_TO control_VB for_IN the_DT deadspace_NN of_IN the_DT filter_NN ,_, and_CC replaced_VBD this_DT volume_NN with_IN heparinized_JJ saline_NN ._SENT The_DT circuits_NNS were_VBD driven_VBN by_IN the_DT arterial_JJ blood_NN pressure_NN ._SENT The_DT replacement_NN fluid_NN consisted_VBN of_IN the_DT following_NN :_: 1:1_CD replacement_NN of_IN blood_NN with_IN 6_CD %_NN Hetastarch_NN in_IN saline_NN ,_, and_CC 1:1_CD replacement_NN of_IN ultrafiltrate_JJ production_NN with_IN lactated_VBN Ringer_NP 's_POS solution_NN ._SENT We_PP infused_VBD the_DT lactated_VBN Ringer_NP 's_POS solution_NN as_IN predilution_NN into_IN the_DT arterial_JJ limb_NN of_IN the_DT hemofilter_NN ._SENT We_PP gave_VBD the_DT Hetastarch_NN through_IN the_DT catheter_NN in_IN the_DT femoral_JJ vein_NN ._SENT We_PP collected_VBD the_DT ultrafiltrate_NN and_CC measured_VBD it_PP twice_RB an_DT hour_NN to_TO maintain_VB an_DT accurate_JJ replacement_NN rate_NN (_( average_NN 30_CD ml/hour_NN )_) ._SENT We_PP began_VBD replacing_VBG the_DT ultrafiltrate_NN after_IN the_DT first_JJ half-hour_NN ._SENT For_IN animals_NNS in_IN group_NN 3_CD ,_, we_PP reinfused_VBD ultrafiltrate_NNS as_IN replacement_NN fluid_NN ._SENT We_PP chose_VBD to_TO study_VB reinfusion_NN rather_RB than_IN ultrafiltrate_NNS clamping_VBG because_IN sieving_VBG may_MD augment_VB adsorption_NN by_IN increasing_VBG the_DT effective_JJ surface_NN area_NN of_IN the_DT membrane_NN by_IN exposing_VBG more_JJR of_IN the_DT inner_JJ matrix_NN of_IN the_DT filter_NN to_TO plasma_NN ._SENT Blood_NN was_VBD drawn_VBN from_IN all_PDT the_DT animals_NNS at_IN hours_NNS 9_CD ,_, 14_CD and_CC 20_CD ._SENT The_DT initial_JJ blood_NN sample_NN included_VBD blood_NN for_IN blood_NN gas_NN analysis_NN (_( 1.0_CD ml_NN total_NN )_) ._SENT All_DT other_JJ blood_NN samples_NNS were_VBD 0.75_CD ml_NN ._SENT We_PP measured_VBD the_DT hemoglobin_NN concentration_NN and_CC oxygen_NN saturation_NN in_IN each_DT blood_NN sample_NN using_VBG an_DT OSM3_NP Hemoximeter_NP (_( Radiometer_NP America_NP ,_, Inc_NP ,_, Westlake_NP ,_, Ohio_NP ,_, USA_NP )_) to_TO ensure_VB that_IN the_DT animal_NN was_VBD neither_RB hypovolemic_JJ nor_CC hypoxic_JJ ._SENT The_DT blood_NN sample_NN was_VBD divided_VBN into_IN two_CD 0.4-ml_NN chilled_VBN tubes_NNS containing_VBG EDTA_NP (_( 1_CD mg/ml_NN )_) and_CC centrifuged_VBD immediately_RB at_IN 1000_CD g_NN for_IN 10_CD minutes_NNS ._SENT The_DT plasma_NN was_VBD drawn_VBN off_RP ,_, placed_VBN into_IN 0.5-ml_NN labeled_VBN microtubes_NNS and_CC stored_VBN at_IN -70C_NN for_IN later_RBR cytokine_JJ analysis_NN ._SENT The_DT animals_NNS remained_VBD anesthetized_VBN and_CC on_IN the_DT ventilator_NN until_IN the_DT 20th_JJ hour_NN after_IN the_DT laparotomy_NN ,_, when_WRB we_PP killed_VBD them_PP humanely_RB ._SENT Measurements_NNS and_CC calculations_NNS |_SYM Plasma_NP concentrations_NNS of_IN IL-6_NP and_CC TNF_NP were_VBD determined_VBN by_IN rat-specific_JJ ELISA_NP according_VBG to_TO manufacturer_NN instructions_NNS (_( Biosource_NP International_NP ,_, Camarillo_NP ,_, CA_NP ,_, USA_NP ,_, and_CC Endogen_NP ,_, Woburn_NP ,_, MA_NP ,_, USA_NP )_) ,_, respectively_RB ._SENT The_DT TNF_NP assay_NN was_VBD linear_JJ from_IN 0_CD to_TO 2500_CD pg/ml_NN ,_, and_CC the_DT IL-6_NP assay_NN was_VBD linear_JJ from_IN 0_CD to_TO 2000_CD pg/ml_NN ;_: coefficients_NNS of_IN variation_NN on_IN repeated_JJ samples_NNS were_VBD less_JJR than_IN 10_CD %_NN for_IN both_DT assays_NNS ._SENT Our_PP$ primary_JJ analysis_NN was_VBD based_VBN on_IN the_DT change_NN in_IN IL-6_JJ concentrations_NNS from_IN the_DT beginning_NN to_TO the_DT end_NN of_IN the_DT hemofiltration_NN (_( 9_CD hours_NNS versus_IN 20_CD hours_NNS )_) across_IN the_DT three_CD groups_NNS ._SENT The_DT absolute_JJ changes_NNS in_IN IL-6_NP concentrations_NNS were_VBD compared_VBN using_VBG one-way_JJ analysis_NN of_IN variance_NN (_( ANOVA_NP )_) followed_VBD by_IN the_DT Student-Newman-Keuls_NP (_( SNK_NP )_) multiple_JJ comparison_NN test_NN ._SENT Our_PP$ secondary_JJ analysis_NN of_IN TNF_NP concentrations_NNS was_VBD performed_VBN after_IN calculating_VBG the_DT area_NN under_IN the_DT curve_NN (_( AUC_NP )_) formed_VBD by_IN three_CD measurements_NNS (_( at_IN 9_CD ,_, 14_CD and_CC 20_CD hours_NNS )_) and_CC zeroed_VBN by_IN the_DT baseline_NN (_( 9_CD hours_NNS )_) levels_NNS ._SENT Mean_JJ areas_NNS were_VBD compared_VBN for_IN each_DT group_NN using_VBG ANOVA/SNK_JJ analysis_NN as_IN per_IN IL-6_NP above_RB ._SENT The_DT absolute_JJ changes_NNS in_IN IL-6_NP were_VBD correlated_VBN across_IN all_DT groups_NNS with_IN the_DT TNF_NP AUC_NP ,_, using_VBG linear_JJ regression_NN ._SENT All_DT statistical_JJ tests_NNS were_VBD performed_VBN using_VBG MedCalc_NP (_( v_NN 4.2_CD ,_, Mariakerke_NP ,_, Belgium_NP )_) software_NN and_CC statistical_JJ significance_NN was_VBD assumed_VBN for_IN P_NN <_SYM 0.05_CD ._SENT Unless_IN specified_VBN otherwise_RB ,_, all_DT results_NNS are_VBP presented_VBN as_IN means_NN +-_NN standard_JJ deviation_NN ._SENT In_IN the_DT two_CD animals_NNS used_VBN for_IN mapping_VBG IL-6_NP and_CC TNF_NP responses_NNS to_TO CLP_NP ,_, we_PP found_VBD results_NNS consistent_JJ with_IN those_DT of_IN other_JJ investigators_NNS ._SENT Namely_RB ,_, plasma_NN IL-6_NN concentrations_NNS rose_VBD steadily_RB ,_, peaking_VBG between_IN 18_CD and_CC 20_CD hours_NNS after_IN CLP_NP ,_, whereas_IN no_DT consistent_JJ pattern_NN emerged_VBD for_IN plasma_NN TNF_NP levels_NNS ._SENT The_DT results_NNS for_IN the_DT three_CD groups_NNS are_VBP shown_VBN in_IN Table_NP ._SENT IL-6_NP levels_NNS were_VBD not_RB significantly_RB different_JJ among_IN the_DT three_CD groups_NNS at_IN baseline_NN and_CC at_IN 5_CD hours_NNS ._SENT However_RB ,_, IL-6_NP levels_NNS increased_VBD in_IN the_DT sham-treated_JJ animals_NNS (_( group_NN 1_CD )_) from_IN baseline_NN to_TO 11_CD hours_NNS (_( see_VB Table_NP ;_: P_NN =_SYM 0.03_CD )_) (_( differences_NNS between_IN groups_NNS 1_CD and_CC 2_CD ,_, P_NN =_SYM 0.015_CD and_CC groups_VBZ 1_CD and_CC 3_CD ,_, P_NN =_SYM 0.028_CD )_) ._SENT TNF_NP levels_NNS were_VBD highly_RB variable_JJ between_IN and_CC within_IN animals_NNS ._SENT TNF_NP AUC_NP analysis_NN was_VBD not_RB significantly_RB different_JJ among_IN the_DT three_CD groups_NNS ,_, although_IN the_DT trend_NN was_VBD in_IN the_DT same_JJ direction_NN as_IN for_IN IL-6_NP ,_, in_IN that_DT group_NN 1_CD tended_VBN to_TO have_VB the_DT highest_JJS TNF_NP concentrations_NNS (_( 453_CD +-_NN 509_CD pg/ml_NN per_IN 11_CD hours_NNS )_) ,_, group_NN 2_CD the_DT lowest_JJS (_( 160_CD +-_NN 443_CD pg/ml_NN per_IN 11_CD hours_NNS )_) and_CC group_VB 3_CD intermediate_JJ (_( 359_CD +-_NN 377_CD pg/ml_NN per_IN 11_CD hours_NNS )_) ._SENT The_DT relation_NN between_IN the_DT change_NN in_IN IL-6_NP and_CC the_DT TNF_NP AUC_NP is_VBZ shown_VBN in_IN Fig._NN ._SENT The_DT weak_JJ correlation_NN between_IN the_DT two_CD as_RB shown_VBN by_IN linear_JJ regression_NN was_VBD not_RB statistically_RB significant_JJ ._SENT Figure_NP 1_CD |_SYM Plasma_NP IL-6_NP concentrations_NNS in_IN rats_NNS before_IN (_( light_JJ bars_NNS )_) and_CC after_IN (_( dark_JJ bars_NNS )_) 11_CD hours_NNS of_IN hemofiltration_NN started_VBD 9_CD hours_NNS after_IN cecal_JJ ligation_NN and_CC puncture_VB (_( CLP_NP )_) ._SENT Plasma_NN IL-6_NN concentrations_NNS in_IN rats_NNS before_IN (_( light_JJ bars_NNS )_) and_CC after_IN (_( dark_JJ bars_NNS )_) 11_CD hours_NNS of_IN hemofiltration_NN started_VBD 9_CD hours_NNS after_IN cecal_JJ ligation_NN and_CC puncture_VB (_( CLP_NP )_) ._SENT Animals_NNS in_IN group_NN 1_CD underwent_VBD CLP_NP with_IN sham_JJ hemofiltration_NN ._SENT Animals_NNS in_IN group_NN 2_CD underwent_VBD CLP_NN and_CC hemofiltration_NN ._SENT Animals_NNS in_IN group_NN 3_CD underwent_VBD CLP_NN and_CC hemofiltration_NN with_IN reinfusion_NN of_IN the_DT ultrafiltrate_NN intravenously_RB ._SENT Heights_NNS of_IN bars_NNS correspond_VBP to_TO mean_VB IL-6_JJ levels_NNS ;_: error_NN bars_NNS =_SYM SEM_NP ._SENT Significant_JJ differences_NNS were_VBD found_VBN for_IN group_NN 1_CD before_IN versus_CC after_IN ,_, and_CC after_IN hemofiltration_NN between_IN groups_NNS 1_CD and_CC 2_CD and_CC 1_CD and_CC 3_CD (_( P_NN <_SYM 0.05_CD )_) ._SENT SEM_NP ,_, standard_JJ error_NN of_IN the_DT mean_NN ._SENT Figure_NP 2_CD |_SYM Scatter_NP plot_NN of_IN tumor_NN necrosis_NN factor_NN area-under-the-curve_NN (_( TNF_NP AUC_NP )_) versus_CC the_DT change_NN in_IN IL-6_NP before_IN and_CC after_IN hemofiltration_NN in_IN rats_NNS that_WDT had_VBD undergone_VBN cecal_JJ ligation_NN and_CC puncture_NN ._SENT Scatter_NN plot_NN of_IN tumor_NN necrosis_NN factor_NN area-under-the-curve_NN (_( TNF_NP AUC_NP )_) versus_CC the_DT change_NN in_IN IL-6_NP before_IN and_CC after_IN hemofiltration_NN in_IN rats_NNS that_WDT had_VBD undergone_VBN cecal_JJ ligation_NN and_CC puncture_NN ._SENT The_DT regression_NN line_NN was_VBD determined_VBN by_IN linear_JJ regression_NN (_( y_NP =_SYM 0.0289x_NN +_SYM 2.1158_CD )_) ,_, r_NN =_SYM 0.3217_CD (_( 95_CD %_NN confidence_NN interval_NN for_IN r_NN =_SYM -0.1709_CD to_TO 0.6856_CD )_) ._SENT Table_NP 1_CD |_SYM Cytokine_JJ concentrations_NNS (_( pg/ml_VB ;_: mean_VB +-_NP SEM_NP )_) found_VBD in_IN rats_NNS after_IN cecal_JJ ligation_NN and_CC puncture_NN followed_VBN by_IN hemofiltration_NN Our_NN findings_NNS show_VBP that_IN the_DT inflammatory_JJ response_NN induced_VBN by_IN CLP_NP and_CC characterized_VBN by_IN a_DT steady_JJ increase_NN in_IN circulating_VBG IL-6_JJ levels_NNS over_IN 18_CD --_: 24_CD hours_NNS can_MD be_VB inhibited_VBN to_TO a_DT similar_JJ degree_NN by_IN hemofiltration_NN whether_IN or_CC not_RB the_DT ultrafiltrate_NN is_VBZ reinfused_VBN ._SENT These_DT findings_NNS provide_VBP strong_JJ evidence_NN that_IN immunomodulation_NN seen_VBN with_IN hemofiltration_NN is_VBZ predominantly_RB the_DT result_NN of_IN adsorption_NN of_IN circulating_VBG mediator_NN substances_NNS to_TO the_DT filter_NN membrane_NN ._SENT Future_JJ studies_NNS of_IN hemofiltration_NN in_IN sepsis_NN might_MD be_VB more_RBR successful_JJ if_IN steps_NNS are_VBP taken_VBN to_TO maximize_VB adsorption_NN ._SENT Our_PP$ findings_NNS also_RB confirm_VBP those_DT of_IN our_PP$ previous_JJ trial_NN in_IN humans_NNS and_CC work_NN from_IN other_JJ groups_NNS showing_VBG that_IN biologically_RB significant_JJ immunomodulation_NN can_MD and_CC does_VBZ occur_VB with_IN continuous_JJ hemofiltration_NN ._SENT However_RB ,_, the_DT clinical_JJ significance_NN of_IN these_DT changes_NNS remain_VBP in_IN question_NN ._SENT Unlike_IN therapies_NNS designed_VBN to_TO target_VB specific_JJ mediators_NNS ,_, hemofiltration_NN has_VBZ the_DT theoretical_JJ advantage_NN of_IN being_VBG at_IN once_RB selective_JJ and_CC nonspecific_JJ ._SENT Hemofiltration_NP is_VBZ selective_JJ in_IN the_DT sense_NN that_IN it_PP will_MD affect_VB circulating_VBG substances_NNS in_IN direct_JJ proportion_NN to_TO their_PP$ concentrations_NNS in_IN the_DT plasma_NN ,_, but_CC nonspecific_JJ in_IN that_IN it_PP will_MD remove_VB multiple_JJ substances_NNS ,_, both_CC proinflammatory_JJ and_CC anti-inflammatory_JJ ._SENT This_DT feature_NN makes_VBZ hemofiltration_NN quite_RB different_JJ from_IN other_JJ forms_NNS of_IN immunomodulation_NN that_WDT target_VBP specific_JJ mediators_NNS and_CC reduce_VB their_PP$ concentration_NN regardless_RB of_IN the_DT baseline_JJ levels_NNS ._SENT Hemofiltration_NP has_VBZ been_VBN shown_VBN remove_VB a_DT wide_JJ variety_NN of_IN biologically_RB active_JJ substances_NNS ,_, many_JJ of_IN which_WDT are_VBP known_VBN to_TO be_VB involved_VBN in_IN the_DT regulation_NN of_IN host_NN defense_NN ,_, inflammation_NN and_CC tissue_NN repair_NN ._SENT However_RB ,_, controversy_NN exists_VBZ as_RB to_TO the_DT primary_JJ mechanism_NN responsible_JJ for_IN this_DT effect_NN ._SENT We_PP have_VBP previously_RB shown_VBN ,_, in_IN patients_NNS with_IN sepsis_NN ,_, that_DT time-weighted_JJ mean_JJ TNF_NP concentrations_NNS decreased_VBD during_IN continuous_JJ venovenous_JJ hemofiltration_NN but_CC increased_VBN if_IN the_DT same_JJ patients_NNS were_VBD treated_VBN with_IN continuous_JJ venovenous_JJ hemodialysis_NN ._SENT Despite_IN these_DT changes_NNS in_IN circulating_VBG TNF_NP levels_NNS ,_, only_RB trace_VB amounts_NNS of_IN TNF_NP were_VBD recovered_VBN from_IN the_DT ultrafiltrate_NN ._SENT Subsequently_RB ,_, other_JJ groups_NNS have_VBP found_VBN similar_JJ results_NNS in_IN patients_NNS treated_VBN with_IN continuous_JJ venovenous_JJ hemofiltration_NN on_IN cardiopulmonary_JJ bypass_NN or_CC in_IN patients_NNS with_IN septic_JJ shock_NN ._SENT However_RB ,_, both_CC of_IN these_DT recent_JJ studies_NNS showed_VBD only_RB early_JJ ,_, transient_JJ reductions_NNS in_IN plasma_NN cytokines_NNS ,_, suggesting_VBG that_IN filter_NN saturation_NN occurs_VBZ after_IN several_JJ hours_NNS of_IN therapy_NN ._SENT The_DT various_JJ membranes_NNS currently_RB available_JJ differ_VBP significantly_RB from_IN one_CD another_DT in_IN their_PP$ adsorptive_JJ capacity_NN for_IN mediators_NNS ._SENT Indeed_RB ,_, the_DT majority_NN of_IN studies_NNS of_IN hemofiltration_NN in_IN sepsis_NN have_VBP failed_VBN to_TO find_VB any_DT change_NN in_IN circulating_VBG mediator_NN concentrations_NNS ._SENT These_DT observations_NNS have_VBP led_VBN to_TO the_DT development_NN of_IN combined_JJ hemofiltration/hemoadsorption_NN techniques_NNS ,_, which_WDT are_VBP beginning_VBG to_TO show_VB promise_NN in_IN animal_JJ studies_NNS ._SENT Our_PP$ results_NNS do_VBP not_RB exclude_VB a_DT possible_JJ role_NN for_IN mechanisms_NNS other_JJ than_IN adsorption_NN ._SENT Several_JJ investigators_NNS have_VBP found_VBN an_DT association_NN between_IN increased_VBN ultrafiltration_NN rates_NNS and_CC improvement_NN in_IN hemodynamic_JJ stability_NN in_IN both_DT animals_NNS and_CC humans_NNS with_IN septic_JJ shock_NN ._SENT It_PP may_MD be_VB that_IN these_DT improvements_NNS in_IN hemodynamic_JJ stability_NN do_VBP not_RB involve_VB cytokine_NN removal_NN ._SENT Furthermore_RB ,_, filtration_NN appears_VBZ to_TO augment_VB adsorption_NN ,_, so_RB that_DT combined_JJ filtration/adsorption_NN might_MD be_VB more_RBR effective_JJ than_IN adsorption_NN alone_RB ,_, at_IN least_JJS when_WRB hollow-fiber_NN dialyzers_NNS are_VBP used_VBN ._SENT Other_JJ methods_NNS of_IN increasing_VBG adsorption_NN might_MD be_VB even_RB more_RBR effective_JJ ._SENT A_DT major_JJ limitation_NN to_TO our_PP$ study_NN is_VBZ the_DT fact_NN that_IN we_PP cannot_MD distinguish_VB between_IN increased_VBN IL-6_JJ removal_NN and_CC decreased_VBD IL-6_JJ production_NN as_IN the_DT cause_NN for_IN the_DT observed_JJ attenuation_NN in_IN IL-6_NP response_NN to_TO CLP_NP ._SENT We_PP chose_VBD to_TO use_VB IL-6_NP as_IN our_PP$ marker_NN of_IN the_DT inflammatory_JJ response_NN because_IN ,_, unlike_IN many_JJ other_JJ cytokines_NNS ,_, its_PP$ plasma_NN concentrations_NNS have_VBP been_VBN directly_RB correlated_VBN with_IN risk_NN of_IN death_NN in_IN intra-abdominal_JJ sepsis_NN in_IN humans_NNS ,_, and_CC measurements_NNS of_IN this_DT single_JJ parameter_NN predicted_VBD outcome_NN in_IN these_DT cases_NNS with_IN remarkable_JJ (_( 82.9_CD %_NN )_) accuracy_NN ._SENT Furthermore_RB ,_, although_IN IL-6_NP is_VBZ not_RB directly_RB cytotoxic_JJ ,_, there_EX is_VBZ evidence_NN that_IN it_PP modulates_VBZ other_JJ inflammatory_JJ cytokines_NNS ,_, and_CC plasma_NN concentrations_NNS have_VBP been_VBN found_VBN to_TO be_VB 69_CD %_NN (_( 95_CD %_NN confidence_NN interval_NN 30%-108_CD %_NN )_) higher_JJR in_IN nonsurvivors_NNS than_IN in_IN survivors_NNS with_IN sepsis_NN ._SENT Many_JJ studies_NNS have_VBP shown_VBN an_DT association_NN between_IN mean_JJ plasma_NN IL-6_NN concentrations_NNS over_IN time_NN and_CC mortality_NN ,_, and_CC persistent_JJ elevations_NNS in_IN IL-6_NP appear_VBP to_TO be_VB more_RBR important_JJ than_IN initial_JJ or_CC peak_JJ levels_NNS ._SENT However_RB ,_, plasma_NN IL-6_NN levels_NNS reflect_VBP both_DT clearance_NN (_( endogenous_JJ and_CC exogenous_JJ )_) and_CC production_NN ,_, and_CC IL-6_NP production_NN is_VBZ largely_RB determined_VBN by_IN the_DT activity_NN of_IN other_JJ proinflammatory_JJ cytokines_NNS (_( especially_RB IL-1_NP and_CC TNF_NP )_) ._SENT Thus_RB ,_, hemofiltration_NN may_MD attenuate_VB the_DT sepsis-induced_JJ rise_NN in_IN IL-6_NP by_IN adsorption_NN of_IN IL-6_NP or_CC by_IN adsorption_NN of_IN other_JJ mediators_NNS or_CC both_DT ._SENT Indeed_RB ,_, it_PP seems_VBZ likely_RB that_IN our_PP$ findings_NNS resulted_VBN from_IN a_DT downregulation_NN in_IN the_DT inflammatory_JJ response_NN to_TO CLP_NP ._SENT This_DT explanation_NN is_VBZ speculative_JJ ,_, however_RB ,_, because_IN we_PP could_MD not_RB demonstrate_VB a_DT corresponding_JJ decrease_NN in_IN plasma_NN TNF_NP ._SENT Analysis_NN of_IN plasma_NN TNF_NP concentrations_NNS is_VBZ more_RBR complex_JJ than_IN of_IN IL-6_NP ,_, because_IN the_DT TNF_NP response_NN is_VBZ already_RB waning_VBG by_IN 9_CD hours_NNS after_IN CLP_NP and_CC is_VBZ much_RB more_RBR variable_JJ ._SENT Furthermore_RB ,_, we_PP measured_VBD total_JJ TNF_NP and_CC do_VBP not_RB know_VB the_DT proportion_NN that_WDT was_VBD biologically_RB active_JJ at_IN the_DT time_NN ._SENT We_PP chose_VBD to_TO analyze_VB TNF_NP using_VBG AUC_NP because_IN of_IN these_DT concerns_NNS and_CC because_IN the_DT effects_NNS of_IN TNF_NP over_IN time_NN presumably_RB relate_VBP to_TO outcome_NN and_CC to_TO IL-6_NP expression_NN more_RBR than_IN to_TO a_DT concentration_NN at_IN a_DT single_JJ time_NN point_NN ._SENT Unfortunately_RB ,_, the_DT smallness_NN of_IN the_DT animals_NNS precluded_VBD multiple_JJ sampling_NN and_CC we_PP selected_VBD only_RB three_CD time_NN points_NNS in_IN order_NN to_TO obtain_VB the_DT '_'' curve_NN '_'' used_VBN for_IN AUC_NP analysis_NN ._SENT These_DT limitations_NNS and_CC the_DT small_JJ sample_NN size_VBP perhaps_RB explain_VB why_WRB we_PP were_VBD only_RB able_JJ to_TO show_VB a_DT weak_JJ correlation_NN between_IN TNF_NP AUC_NP and_CC changes_NNS in_IN IL-6_JJ concentrations_NNS over_IN time_NN ._SENT Finally_RB ,_, we_PP must_MD acknowledge_VB that_IN our_PP$ animal_JJ model_NN of_IN sepsis_NN ,_, like_IN sepsis_NN in_IN humans_NNS ,_, is_VBZ associated_VBN with_IN a_DT variable_JJ inflammatory_JJ response_NN ._SENT However_RB ,_, both_DT absolute_JJ and_CC relative_JJ changes_NNS in_IN IL-6_NP levels_NNS appear_VBP similar_JJ with_IN hemofiltration_NN with_IN or_CC without_IN recirculation_NN of_IN ultrafiltrate_NNS ._SENT These_DT results_NNS suggest_VBP that_IN adsorption_NN is_VBZ the_DT primary_JJ ,_, though_RB perhaps_RB not_RB the_DT sole_NN ,_, mechanism_NN responsible_JJ for_IN changes_NNS in_IN IL-6_JJ levels_NNS during_IN hemofiltration_NN ._SENT Changes_NNS in_IN IL-6_NP seen_VBN with_IN hemofiltration_NN are_VBP predominantly_RB the_DT result_NN of_IN adsorption_NN of_IN circulating_VBG inflammatory_JJ mediator_NN substances_NNS to_TO the_DT filter_NN membrane_NN Biologically_NP significant_JJ immunomodulation_NN can_MD and_CC does_VBZ occur_VB with_IN continuous_JJ hemofiltration_NN at_IN blood_NN flow_NN rates_NNS currently_RB in_IN use_NN in_IN clinical_JJ practice_NN We_PP cannot_MD distinguish_VB between_IN increased_VBN IL-6_JJ removal_NN and_CC decreased_VBD IL-6_JJ production_NN as_IN the_DT cause_NN for_IN the_DT attenuation_NN in_IN the_DT IL-6_NP response_NN to_TO sepsis_NN observed_VBD with_IN hemofiltration_NN Future_JJ studies_NNS of_IN hemofiltration_NN in_IN sepsis_NN might_MD be_VB more_RBR successful_JJ if_IN steps_NNS are_VBP taken_VBN to_TO maximize_VB adsorption_NN None_NN declared_VBD ._SENT ANOVA_NN =_SYM one-way_JJ analysis_NN of_IN variance_NN ;_: AUC_NP =_SYM area_NN under_IN the_DT curve_NN ;_: CLP_NP =_SYM cecal_JJ ligation_NN and_CC puncture_NN ;_: ELISA_NP =_SYM enzyme-linked_JJ immunosorbent_JJ assay_NN ;_: IL_NP =_SYM interleukin_NN ;_: SNK_NP =_SYM Student-Newman-Keuls_VBZ ;_: TNF_NP =_SYM tumor_NN necrosis_NN factor_NN ._SENT 